Does Treatment Timing Matter in Lung Cancer?
Does Immunotherapy Treatment Timing Matter in Lung Cancer?
Could Timing Give Your Cancer Treatment a Boost?
A new clinical trial is sparking real conversation in the lung cancer community by asking a surprisingly simple question: Does the time of day you receive treatment affect how well it works? For people living with advanced non-small cell lung cancer (NSCLC), this research offers a hopeful — and low-cost — idea that could one day improve outcomes without changing the drugs themselves.
Morning vs. Afternoon Immunotherapy for Lung Cancer
In a randomized clinical trial, researchers found that patients who received immunochemotherapy earlier in the day lived longer and had better control of their cancer compared to those treated later in the afternoon. Immunochemotherapy is a combination of immunotherapy (which helps your immune system recognize and attack cancer) and chemotherapy (which directly kills cancer cells). Patients treated earlier had a 60% lower risk of cancer progression and a 48% lower risk of early death.
What the Study Found — In Plain Language
The phase 3 LungTIME-C01 trial followed 210 people with advanced (stage IIIC or stage 4) non-small cell lung cancer who did not have known genetic driver mutations. Everyone received the same drugs — the only difference was when treatment was given:
-
Early group: Treatment before 3:00 PM
-
Late group: Treatment after 3:00 PM
After more than two years of follow-up, the differences were striking:
-
Cancer stayed under control for about 11 months in the early-day group
-
Cancer worsened in about 6 months for those treated later
-
Overall survival was 28 months vs. 16.8 months, favoring earlier treatment
Researchers believe this benefit may be tied to the body’s circadian rhythm — the natural 24-hour cycle that regulates hormones, immune activity, and cell behavior.
Why the Immune System’s “Clock” Matters
Your immune system doesn’t work the same way all day long. Certain immune cells — especially CD8+ T cells, often called “killer” T cells — appear to be more active and effective earlier in the day.
In this study, patients treated in the morning had:
-
More circulating CD8+ T cells
-
A healthier balance of activated (ready to fight cancer) vs. exhausted immune cells
This may explain why immunotherapy worked better earlier in the day — the immune system was simply more prepared to respond.
Should Patients Change Their Treatment Time Now?
Not yet — and that’s important to say clearly.
While many experts find the results exciting, others urge caution. This is the first randomized trial to confirm what earlier observational studies only suggested. Larger studies and reviews of past trials are still needed before treatment timing becomes part of standard care.
That said, this approach is especially intriguing because:
-
It doesn’t add new drugs
-
It doesn’t increase toxicity
-
It could be easier to implement than many medical advances
Some researchers believe timing may matter most during the first cycle of immunotherapy, when the immune system is being “trained” to recognize cancer.
What This Means for Patients Today
If you’re receiving or considering immunochemotherapy:
-
Timing is not part of standard treatment guidelines yet
-
This study is promising, but still early
-
It may be worth asking your oncologist whether infusion timing is flexible — especially at the start of treatment
As always, treatment decisions should be personalized, balancing science, logistics, and what’s realistic for you.
At Stage4Hope, we believe progress often comes from unexpected places — and sometimes, hope comes from asking new questions about familiar treatments. We’ll continue to follow this research closely and share updates as more data becomes available.
Questions to Ask Your Doctor
-
Does treatment timing matter for my specific cancer?
-
Is morning treatment an option for me?
-
How does immunotherapy work with my immune system?
-
What side effects should I watch for?
Stay Connected with Stage 4 Hope
AI in Lung Cancer Treatment
How AI Is Improving Lung Cancer Treatment: New Tools, Real Impact
See how AI is helping guide immunotherapy decisions, combine imaging for deeper insights, and support earlier detection—bringing more personalized lung cancer care.
Three Ways AI Is Moving Lung Cancer Care Forward
1) AI that predicts immunotherapy response in advanced NSCLC (Deep-IO)
A validated deep-learning model called Deep-IO may help doctors better predict which patients with advanced non-small cell lung cancer (NSCLC) will respond to immunotherapy—using routine pathology slides from tumor biopsies. In the study discussed in a Physician’s Weekly Q&A, researchers trained the model on hundreds of thousands of image “tiles” from 958 patients (US + EU cohorts, 2014–2022). The model showed meaningful accuracy for predicting response (reported AUCs varied by cohort) and, importantly, it may help identify non-responders more specifically—potentially sparing patients ineffective treatment and side effects. The article also notes that combining Deep-IO + PD-L1 performed better than either marker alone in that validation setting.1
2) “Connecting the dots” across cancer images (Emory)
A separate Emory report highlights how AI is being used to combine different kinds of cancer images—from microscopic tissue slides to CT scans and even epigenetic data—so researchers can build a more complete picture of how a tumor behaves. In four studies (focused on head and neck cancers), one team used an AI platform called VISTA to transform standard H&E slides into “virtual IHC” to help identify tumor-associated macrophages that are otherwise difficult to see. Another approach adapted a swin transformer into a multimodal framework (called SMuRF) that helped integrate 2D pathology images with 3D radiology, supporting predictions about survival and even which patients might benefit from chemotherapy. A fourth effort linked slide images with epigenetic patterns using pathogenomic fingerprinting, aiming to improve risk assessment. Emory’s researchers also emphasize the need to be cautious and thoughtful before moving these tools fully into clinical practice.2
3) What this means for lung cancer patients right now
Together, these developments point to a near-future where AI can support:
- More personalized treatment selection (who is most likely to benefit from immunotherapy)3
- Smarter risk and prognosis tools by combining radiology + pathology + other data4
- Earlier detection and faster pathways to care, especially as imaging AI expands in real-world settings5
It’s also important to keep the balance: experts continue to flag challenges like bias and fairness, the need for diverse multi-site datasets, and careful clinical validation before widespread adoption.6
More examples of AI in cancer research and care
- NCI’s HistoTME model (NSCLC + immunotherapy): An NCI team described HistoTME, which analyzes digital pathology images to learn about the tumor microenvironment and improve prediction of immunotherapy response—supporting biomarker discovery and more personalized immunotherapy strategies.7
- AI-driven early lung cancer detection (Bristol Myers + Microsoft, Jan 20, 2026): Reuters reports a collaboration using FDA-cleared radiology AI algorithms through Microsoft’s Precision Imaging Network to help clinicians detect lung nodules earlier and expand access in underserved communities.8
- AI + breast cancer screening at scale (EDITH trial, UK): A UK government announcement describes a large NHS trial (~700,000 participants) evaluating AI to support mammogram reading and potentially reduce the need for a second specialist reader.9
- Multimodal AI for recurrence risk (AACR, Dec 10, 2025): AACR describes an AI model combining digitized pathology slides with molecular + clinical data to improve long-term recurrence risk stratification in early breast cancer.10
- AI to speed oncology drug research (AstraZeneca + Modella AI, Jan 13, 2026): Reuters reports AstraZeneca agreed to acquire Modella AI to boost quantitative pathology and biomarker discovery for oncology R&D.11
AI is a supportive tool
AI isn’t replacing oncologists—it’s becoming a powerful support tool that can help doctors see patterns humans can’t easily spot, match patients to therapies more precisely, and potentially reduce trial-and-error in treatment. If you or someone you love is living with lung cancer, it may be worth asking your care team about biomarker testing (like PD-L1), available clinical trials, and how new imaging or pathology tools are shaping treatment decisions.12
Resources for Living With Stage 4 Cancer
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Become a member of our community to gain access to trusted resources, as well as online support and more.
References:
- https://www.physiciansweekly.com/post/qa-validated-ai-model-could-guide-real-world-nsclc-decisions
- https://news.emory.edu/stories/2025/06/hs_head_and_neck_16-06-2025/story.html
- https://www.physiciansweekly.com/post/qa-validated-ai-model-could-guide-real-world-nsclc-decisions
- https://news.emory.edu/stories/2025/06/hs_head_and_neck_16-06-2025/story.html
- https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-partners-with-microsoft-ai-driven-lung-cancer-detection-2026-01-20/
- https://www.cancer.gov/about-nci/organization/cbiit/news-events/news/2025/artificial-intelligence-ai-model-histotme-aids-predicting-response-immunotherapy
- https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-partners-with-microsoft-ai-driven-lung-cancer-detection-2026-01-20/
- https://www.gov.uk/government/news/world-leading-ai-trial-to-tackle-breast-cancer-launched
- https://www.aacr.org/about-the-aacr/newsroom/news-releases/a-multimodal-ai-model-may-improve-recurrence-risk-stratification-in-early-breast-cancer/
- https://www.reuters.com/business/healthcare-pharmaceuticals/bristol-myers-partners-with-microsoft-ai-driven-lung-cancer-detection-2026-01-20/
- https://www.physiciansweekly.com/post/qa-validated-ai-model-could-guide-real-world-nsclc-decisions
Safer Cancer Drug Dosing Ahead
Safer Cancer Drug Dosing: ASCO and FDA Push for Optimal, Not Maximum, Doses
ASCO and the FDA promote safer cancer drug dosing by focusing on optimal cancer drug dosing—finding the optimal effective dose to reduce side effects and improve treatment tolerance. Learn more in this article about optimal cancer drug dosing.
Concerns are growing that cancer drugs may be given at higher doses than patients actually need, leading to unnecessary side effects and treatment interruptions. The American Society of Clinical Oncology (ASCO), working with the FDA, has issued new principles urging a shift from the old “maximum tolerated dose” approach toward finding the “optimal effective dose.” This matters for newer treatments like immunotherapies and targeted therapies, where higher doses don’t always improve results but often increase harmful side effects. Patient surveys show many people with advanced cancers struggle with severe treatment side effects, and oncologists frequently lower doses early on to help patients stay on therapy.
To fix this, ASCO recommends designing trials that test multiple dosage levels, tailoring studies to real-world patients, and improving how patient-reported side effects are tracked. These steps align with the FDA’s Project Optimus, which is pushing for better drug dosing in cancer research. For patients, this shift offers hope for treatment that works just as well—or better—while being easier to tolerate, helping people with advanced cancer focus on living fully instead of fighting side effects. (Source: Oncology News Central)
Read the complete article here >
Earlier detection and better-tolerated treatment often go hand in hand. If you’re interested in what’s on the horizon for catching cancer sooner, read Future of Cancer Screening: Multi-Cancer Early Detection Brings New Hope.
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like optimal cancer drug dosing, dosing strategy guidance from ASCO and the FDA, trial design, and initiatives like the FDA’s Project Optimus—along with other aspects of living with late-stage cancer. Join our community to connect with others who understand your experience and gain access to resources, events, medical updates, and invitations to supportive virtual events.
New Clues on How Cancer Spreads
New Clues on Cancer Metastasis: How “Shape-Shifting” Cells Spread and Survive
With cancer metastasis research, researchers uncover how metastatic cancer cells hide, adapt, and return—offering new hope for treatments that stop cancer spread and improve survival.
For decades, doctors have known that cancer’s deadliest threat comes not from the original tumor but from metastasis — when cancer spreads to other parts of the body. Up to 90% of cancer deaths are linked to this process. Now, researchers led by Dr. Joan Massagué at Memorial Sloan Kettering are uncovering important insights into how metastatic cells survive, hide, and return to grow new tumors years later. These “shape-shifting” cells act like stem cells, traveling back in time to earlier, more flexible states that allow them to adapt and resist treatment. They can also slip into dormancy, hiding from the immune system until the conditions are right to awaken and spread again.
Scientists are learning that metastatic cells use different strategies depending on the type of cancer and the organ they invade. They can even change their physical shape to avoid being destroyed by the immune system. These discoveries open new possibilities for treatment — from targeting the hidden “time traveler” state, to waking dormant cells so the immune system can attack them, to blocking proteins that allow cancer cells to evade detection. While challenges remain, Dr. Massagué emphasizes that metastasis is no longer an automatic death sentence. With advances in immunotherapy and targeted research, controlling — and in some cases curing — stage 4 cancer is becoming more possible than ever before. (Source: Memorial Sloan Kettering)
Read the complete article here >
As cancer screening evolves, researchers are also rethinking how cancer drugs are dosed to reduce side effects and help patients stay on therapy. Learn more about optimal cancer drug dosing and why “optimal” can matter more than “maximum.”
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about topics like cancer metastasis research, including new findings on how metastasis works—mechanisms like dormancy and “shape-shifting” behavior—and how this research could inform future treatments. Join our community to connect with others who understand your experience and gain access to resources, events, medical updates, and invitations to supportive virtual events.
Second Opinions Can Save Lives
Why Getting a Second Opinion for Cancer Can Save Your Life
Being told you have cancer is overwhelming, and it’s easy to feel pressured to start treatment right away. But getting a second opinion can make a huge difference—it may confirm the diagnosis, catch mistakes, or suggest new treatment options. For patients with stage 4 or hard-to-treat lung cancer, this extra step can open the door to advanced therapies and clinical trials not available everywhere.
Specialists at National Cancer Institute-designated centers look deeper than a single test. They review scans, biopsy slides, and genetic testing to match you with the best targeted therapy or immunotherapy. Many doctors welcome second opinions, and sometimes both teams can work together—giving you more support, not less.
Most importantly, a second opinion can give you peace of mind. Knowing your diagnosis and plan have been double-checked helps you move forward with confidence and focus on what matters most: your care and your life. (Source: Winship Magazine)
Read the complete article here >
You’re Not Alone—Connect with the Stage 4 Hope Community
Whether you’re navigating treatment options, seeking emotional support, or trying to make sense of a new diagnosis, Stage 4 Hope is here for you. Learn more about practical guidance that can shape treatment decisions, like getting a second opinion and working with specialists. Explore genetic testing and treatment options such as targeted therapy, immunotherapy, and clinical trials. Join our community to connect with others who understand your experience.
Immune Cells Team Up to Kill Tumors
How Immune Cells Work Together to Kill Tumors
How immune cells work together to kill tumors is becoming clearer thanks to a promising new discovery from scientists at Emory’s Winship Cancer Institute. They found that two types of immune cells — T helper 17 (Th17) cells and B cells — can work together to destroy solid tumors and help prevent them from returning. This partnership was unexpected, as most immunotherapies have focused on T cells alone. But in this study, Th17 cells only succeeded in protecting against cancer when B cells were present. These B cells didn’t just help — they produced powerful tumor-fighting antibodies that continued to protect the body long after treatment.
Why does this matter for patients with advanced or treatment-resistant cancer? This research points to a new path in immunotherapy: using the body’s own cells, not just to attack tumors, but to create lasting protection. It could lead to therapies that are more effective for cancers that haven’t responded to current treatments. And because the therapy worked even after the cancer came back in the study’s models, it holds special hope for preventing recurrence — a critical concern for anyone living with stage 4 cancer. A version of this therapy is already being developed for human use. (Source: Emory University Winship Cancer Institute)
Resources for Living With Stage 4 Cancer
Learn more about topics like how immune cells kill tumors, along with other important aspects of living with Stage 4 cancer. Become a member of our community to gain access to trusted resources, online support and education from Dr. Sharon May, Ph.D., LMFT, medical updates, and invitations to supportive virtual gatherings.
Boosting Cancer Immunity Through Fasting
Fasting and Cancer Immunity Explained
How Fasting May Supercharge the Immune System to Better Fight Cancer…
More than a dozen types of cancer are sensitive to obesity, which can cause inflammation that damages cells, increased hormone levels, and other changes. So it makes sense for researchers to explore whether fasting to slow body fat and improve metabolic health might improve outcomes.
Now laboratory researchers at Memorial Sloan Kettering Cancer Center (MSK) and their collaborators have found that fasting can SUPERCHARGE the immune system’s “natural killer” cells. (Natural killer cells, or NK cells, for short, are a type of white blood cell that can kill abnormal or damaged cells, such as cancer cells.)
Fasting can reprogram the metabolism of natural killer cells, the team found in a study of mice. Those reprogrammed cells are better able to survive in the harsh environment in and around tumors. Their cancer-fighting ability is stronger, too.
The research, which was published in Immunity — one of the top immunology journals — explains how natural killer cells get reprogrammed during periods of fasting. The researchers are optimistic that what they’re learning in animal models could help make human immunotherapies more effective in people.
“Tumors are very hungry,” says immunologist Joseph Sun, PhD, the study’s senior author. “They use up the essential nutrients flowing to normal tissue. In that nutrient-starved environment, it is harder for natural killer cells to survive, so their function is impaired. Fasting reprograms these natural killer cells to better survive in this suppressive environment.”
What Are Natural Killer Cells?
Natural killer cells get their name because they can destroy a threat without having to recognize that threat — unlike other immune cells, called T cells, which require exposure to a specific threat in order to target it.
In general, the more NK cells that are present within a tumor, the better the prognosis is for the patient.
How Fasting Reprograms and Redistributes NK Cells
For the study, mice with cancer were fasted for 24 hours twice a week and then allowed to eat freely in between fasts. While the mice did not lose weight, the fasting had a profound effect on their natural killer immune cells.
Just as happens in humans, fasted mice saw a drop in their glucose levels and a rise in free fatty acids, which are lipids released by fat cells.
“During each of these fasting cycles, NK cells learned to use these fatty acids as an alternative fuel source to glucose,” says study first author Rebecca Delconte, PhD, a postdoctoral fellow in the Sun Lab. “This really improves their response against cancer and helps them survive in the harsh environment around the tumor.”
Fasting also led NK cells to travel to and interact with different parts of the body in big numbers. Many of the NK cells travel into the bone marrow, where they are programmed to develop a more powerful response against cancer. Meanwhile, NK cells that travel to the spleen undergo a separate reprogramming, making them better able to use lipids as a fuel source.
“With both of these mechanisms put together, we find that NK cells will move to the tumor and be primed to better kill the cancer cells,” Dr. Delconte says. “They’re more able to survive in this harsh environment, and their power is strengthened against cancer cells.”
Potential To Improve Cancer Treatments
There are several potential opportunities to advance the mouse-model research toward treating patients in the clinic, the researchers say.
First, clinical trials are already beginning to study the safety and effectiveness of fasting in combination with standard treatments. Another avenue would be to identify drugs that could mimic the underlying mechanisms without requiring patients to fast. Third, small molecules might be able to be put into a pill and taken outside of the body and then administered back to patients to improve treatment effects.
Right now, however, more clinical data is still needed about the effects of fasting for people with cancer, MSK researchers say.
There are many different types of fasting, and some might be helpful while others might be harmful. Patients should speak with their doctors about what’s safe and healthy for their individual situation. (Source: Memorial Sloan Kettering News- 2025, Issue 1)
Resources for Living With Stage 4 Cancer
Learn more about topics like fasting and cancer immunity, fiber, and exercise. Gain access to trusted resources, online support and education from Dr. Sharon May, Ph.D., LMFT, medical updates, and invitations to supportive virtual gatherings.
Hope from Metastasis Research
Hope from Metastasis Research: New Advances for Stage 4 Cancer
Learn how metastasis research is uncovering how cancer spreads and resists treatment, including 3D patient models and new clinical trials offering hope for stage 4 cancer.
Metastasis is when cancer spreads from the original tumor to other parts of the body, and it’s often the toughest part to treat. Researchers at Memorial Sloan Kettering are studying how these metastatic cancer cells change and adapt to survive treatments. They found that metastatic cells can “shift” their identity to better survive, which helps explain why they become harder to stop over time.
At MSK, doctors are creating patient-based 3D models to better understand lung cancer spread and to test how different treatments work. There’s also a clinical trial exploring a drug that stops cancer cells in the brain and spine from stealing iron, which they need to grow and to avoid immune attack. This research is paving the way toward treatments that are more targeted and personalized.
For patients with late-stage or metastatic cancer, these advances offer hope for longer control of the disease and, one day, new ways to stop metastasis altogether. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like metastasis research, along with other important aspects of living with Stage 4 cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Precision Cancer Testing Brings New Hope
Precision Cancer Testing Brings New Hope for Stage 4 Cancer
At Memorial Sloan Kettering’s Center for Molecular Oncology, doctors use advanced testing to find the exact changes in a person’s cancer cells. This helps them choose treatments that specifically target those changes, giving patients a better chance at controlling their cancer. Over the past decade, tests like MSK-IMPACT® have made it possible to check for hundreds of genetic changes, even through simple blood tests, helping people with advanced or rare cancers find personalized therapies. But DNA testing doesn’t show everything, so new tests that look at how cancer cells use genes (called RNA tests) and even check all of a person’s genes (whole-genome sequencing) are coming soon. These tools aim to help patients who don’t respond to current treatments and could also guide immunotherapy, which uses the body’s immune system to fight cancer.
This kind of testing can also find inherited gene changes that increase cancer risk, helping families take steps to prevent cancer early. One inspiring example is patient Michael Wolff, a jazz pianist whose rare cancer was identified through molecular testing. Doctors found a gene mutation that led to a drug treatment which quickly stopped his symptoms and shrank his tumors. His success shows how precise testing can save lives and open the door to new treatments for cancers that were once very hard to treat. For patients with stage 4 or difficult cancers, these advances mean more hope for better, tailored care—and the chance for improved quality of life. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like precision cancer testing for stage 4 cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
Cancer Vaccines Offer New Hope
Cancer Vaccines Offer New Hope: mRNA Breakthroughs for Stage 4 Cancer
Discover how therapeutic and personalized mRNA cancer vaccines are training the immune system to fight advanced cancers, with promising early clinical trial results.
Cancer vaccines, once considered a distant dream, are becoming a hopeful reality thanks to groundbreaking research inspired by the success of COVID-19 mRNA vaccines. Unlike traditional vaccines designed to prevent illnesses, therapeutic cancer vaccines teach the body’s own immune system how to recognize and attack cancer cells. Memorial Sloan Kettering (MSK) researchers, building on ideas first imagined over a century ago, have significantly advanced these vaccines. Dr. David Scheinberg, a leading researcher at MSK, explains that new technologies now allow vaccines to target multiple proteins specific to cancer cells, making treatments more effective and reducing side effects compared to chemotherapy and radiation.
One promising area is personalized mRNA cancer vaccines, custom-made for each patient based on their tumor’s unique characteristics. Early trials, particularly in pancreatic cancer, have shown encouraging results, with vaccinated patients’ immune cells remaining active for years. Additionally, MSK researchers are developing off-the-shelf vaccines targeting common cancer markers, such as WT1, found in leukemia and ovarian cancer. These vaccines could soon offer accessible, affordable options for many patients. The rapid progress in cancer vaccine development at MSK offers genuine optimism, especially for patients fighting advanced or hard-to-treat cancers. (Source: Memorial Sloan Kettering)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like mRNA cancer vaccines for stage 4 cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
When a Cough Could Be Lung Cancer
When a Cough Could Be Lung Cancer: Signs, Risks, and Next Steps
A chronic cough is often just a sign of something like a cold, allergies, or asthma — but in some cases, it may be a warning sign of lung cancer. According to lung cancer experts, including Dr. Fatemeh Ardeshir-Larijani of Emory University, a cough that lasts longer than 8 to 12 weeks, worsens over time, or comes with other symptoms like coughing up blood, chest tightness, or unexplained weight loss should not be ignored. While many types of cough can happen with lung cancer, the most common is a dry, persistent cough that doesn’t go away with typical treatments.
People with lung cancer may also experience pressure in the chest, shortness of breath, or coughing due to fluid buildup around the lungs. Treatments to ease this kind of cough vary. For some, shrinking the tumor with chemotherapy, immunotherapy, or targeted therapy helps reduce coughing. Others may need fluid drained from their lungs or use home remedies like steam, hydration, or honey to manage the symptom. While only a small number of people with a chronic cough actually have lung cancer, it’s especially important for those at high risk — such as longtime smokers — to speak with their doctor and consider annual lung cancer screenings. (Source: Verywell Health)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like chronic cough as a sign of lung cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
New Lung Cancer Treatments Show Real Promise
New 2025 Research Brings Hope for Advanced Lung Cancer
New research shared in 2025 brings hope for people with advanced non-small cell lung cancer. Scientists presented several treatment updates that are helping patients live longer with fewer side effects. One medicine, aumolertinib, helped slow cancer growth—especially when combined with chemotherapy. Aumolertinib is a targeted therapy that blocks the EGFR protein, which drives tumor growth in certain lung cancers. When added to chemotherapy, it has been shown to significantly delay cancer progression and is generally well tolerated. Another drug, JYP0322, worked well for people with a rare type of lung cancer, even when the cancer had spread to the brain. JYP0322 is an investigational ROS1 inhibitor designed to cross the blood-brain barrier, making it effective against brain metastases. Early trials showed promising responses in patients who had previously received other ROS1-targeted treatments.
Other promising treatments are helping people whose cancer carries uncommon genetic changes. A pill called zongertinib helped many patients and caused fewer side effects than older drugs. Zongertinib targets HER2-mutated lung cancer, which is rare but often aggressive. Clinical studies showed it shrinks tumors effectively and causes fewer side effects compared with older treatments. Another new medicine, zoldonrasib, showed early success in shrinking tumors in patients whose cancer had stopped responding to other treatments. While one immune-based drug didn’t work as well as hoped, researchers believe it still has potential. Zoldonrasib, is designed for cancers with the KRAS G12D mutation, a mutation that was historically difficult to treat. Early trial results indicate it can shrink tumors in patients whose cancer no longer responds to standard therapies. Overall, the message is clear: more personalized and effective treatments are on the horizon. (Source: American Association for Cancer Research)
Read the complete article here >
Resources for Living With Stage 4 Cancer
Learn more about topics like advanced lunch cancer. Become a member of our community to gain access to trusted resources, as well as online support and education from Dr. Sharon May, Ph.D., LMFT.
